These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20036293)

  • 1. Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
    Nomura T; Abe Y; Kamada H; Shibata H; Kayamuro H; Inoue M; Kawara T; Arita S; Furuya T; Yamashita T; Nagano K; Yoshikawa T; Yoshioka Y; Mukai Y; Nakagawa S; Taniai M; Ohta T; Serada S; Naka T; Tsunoda S; Tsutsumi Y
    J Control Release; 2011 Jan; 149(1):8-14. PubMed ID: 20036293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.
    Shibata H; Yoshioka Y; Abe Y; Ohkawa A; Nomura T; Minowa K; Mukai Y; Nakagawa S; Taniai M; Ohta T; Kamada H; Tsunoda S; Tsutsumi Y
    Biomaterials; 2009 Dec; 30(34):6638-47. PubMed ID: 19765818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models.
    Shibata H; Yoshioka Y; Ohkawa A; Abe Y; Nomura T; Mukai Y; Nakagawa S; Taniai M; Ohta T; Mayumi T; Kamada H; Tsunoda S; Tsutsumi Y
    Cytokine; 2008 Nov; 44(2):229-33. PubMed ID: 18815054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated interferon gamma expression in the central nervous system of tumour necrosis factor receptor 1-deficient mice with experimental autoimmune encephalomyelitis.
    Wheeler RD; Zehntner SP; Kelly LM; Bourbonnière L; Owens T
    Immunology; 2006 Aug; 118(4):527-38. PubMed ID: 16780563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.
    Inoue M; Ando D; Kamada H; Taki S; Niiyama M; Mukai Y; Tadokoro T; Maenaka K; Nakayama T; Kado Y; Inoue T; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2017 Apr; 292(16):6438-6451. PubMed ID: 28235800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model.
    Jung EJ; Hur M; Kim YL; Lee GH; Kim J; Kim I; Lee M; Han HK; Kim MS; Hwang S; Kim S; Woo AM; Yoon Y; Park HJ; Won J
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1005-13. PubMed ID: 19741152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
    Skundric DS; Huston K; Shaw M; Tse HY; Raine CS
    Lab Invest; 1994 Nov; 71(5):671-9. PubMed ID: 7526038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.
    Inoue M; Tsuji Y; Yoshimine C; Enomoto S; Morita Y; Osaki N; Kunishige M; Miki M; Amano S; Yamashita K; Kamada H; Tsutsumi Y; Tsunoda SI
    J Biol Chem; 2020 Jul; 295(28):9379-9391. PubMed ID: 32398258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis.
    Li FQ; Sempowski GD; McKenna SE; Laskowitz DT; Colton CA; Vitek MP
    J Pharmacol Exp Ther; 2006 Sep; 318(3):956-65. PubMed ID: 16740622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide modulates T-cell inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
    Wang Y; Mei Y; Feng D; Xu L
    J Neurosci Res; 2008 Aug; 86(11):2441-9. PubMed ID: 18438925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Region-specific regulation of inflammation and pathogenesis in experimental autoimmune encephalomyelitis.
    Archambault AS; Sim J; McCandless EE; Klein RS; Russell JH
    J Neuroimmunol; 2006 Dec; 181(1-2):122-32. PubMed ID: 17030428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis.
    Murphy AC; Lalor SJ; Lynch MA; Mills KH
    Brain Behav Immun; 2010 May; 24(4):641-51. PubMed ID: 20138983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fast binding kinetics and conserved 3D structure underlie the antagonistic activity of mutant TNF: useful information for designing artificial proteo-antagonists.
    Mukai Y; Nakamura T; Yoshioka Y; Shibata H; Abe Y; Nomura T; Taniai M; Ohta T; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
    J Biochem; 2009 Aug; 146(2):167-72. PubMed ID: 19386778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis.
    Weishaupt A; Kuhlmann T; Schönrock LM; Toyka KV; Brück W; Gold R
    Acta Neuropathol; 2002 Oct; 104(4):385-90. PubMed ID: 12200625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses.
    Nizri E; Irony-Tur-Sinai M; Lory O; Orr-Urtreger A; Lavi E; Brenner T
    J Immunol; 2009 Nov; 183(10):6681-8. PubMed ID: 19846875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis.
    Morini M; Roccatagliata L; Dell'Eva R; Pedemonte E; Furlan R; Minghelli S; Giunti D; Pfeffer U; Marchese M; Noonan D; Mancardi G; Albini A; Uccelli A
    J Neuroimmunol; 2004 Mar; 148(1-2):146-53. PubMed ID: 14975595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARδ deficient mice develop elevated Th1/Th17 responses and prolonged experimental autoimmune encephalomyelitis.
    Kanakasabai S; Walline CC; Chakraborty S; Bright JJ
    Brain Res; 2011 Feb; 1376():101-12. PubMed ID: 21192919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course.
    Racke MK; Burnett D; Pak SH; Albert PS; Cannella B; Raine CS; McFarlin DE; Scott DE
    J Immunol; 1995 Jan; 154(1):450-8. PubMed ID: 7527821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the mechanisms by which transforming growth factor-beta (TGF-beta) protects against allergic encephalomyelitis. Antagonism between TGF-beta and tumor necrosis factor.
    Santambrogio L; Hochwald GM; Saxena B; Leu CH; Martz JE; Carlino JA; Ruddle NH; Palladino MA; Gold LI; Thorbecke GJ
    J Immunol; 1993 Jul; 151(2):1116-27. PubMed ID: 8335893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination.
    Selmaj K; Raine CS; Cross AH
    Ann Neurol; 1991 Nov; 30(5):694-700. PubMed ID: 1722388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.